Summary
The pharmacokinetics of fleroxacin and its metabolites following a single oral dose of fleroxacin 400mg were examined in 6 healthy subjects and 24 patients with various degrees of renal insufficiency. Plasma and urine samples, collected at various times after administration, were assayed by high performance liquid chromatography (HPLC).
In healthy subjects. Cmax was 6.8 ± 0.7 mg/L; Xmax = about 1h. t½ = 14 ± 2h, total clearance = 4.86 ± 0.72 L/h and the percentage of unchanged fleroxacin excreted in urine in 48 hours was 48 ± 4% (HPLC). Plasma concentrations of metabolites were very low and accounted for no more than 5% of the levels of unchanged fleroxacin.
In uraemic patients Cmax did not change, whatever the degree of renal failure; tmax was increased in patients with a glomerular filtration rate below 0.6 L/h, and Vd/f was independent of the seventy of renal failure. These data suggest that bioavailability of the drug is unchanged. In uraemic patients t½, was prolonged and AUC multiplied by a factor of 2 to 3. A linear relationship was found between total and renal clearances of fleroxacin and crcatinine clearance. Accumulation of N-demethyl-fleroxacin and N-oxide-fleroxacin was very high in uraemic patients, due to slow formation of these metabolites and decreased urinary elimination.
Dialysance of fleroxacin and of its metabolites was approximately 3.6 to 4.8 L/h. These findings suggest that fleroxacin dosage may need to be reduced in patients with severe renal disease; in haemodialysed patients, treated every 2 days, a single dose of fleroxacin 400mg is recommended at the end of each dialysis session.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aoyama H, Inoue M, Mitsuhashi S. In vitro and in vivo antibacterial activity of fleroxacin, a new fluorinated quinolone. Journal of Antimicrobial Chemotherapy 22 (Suppl. D): 99–114, 1988
Balant LP, Dayer P, Fabre J. Consequences of renal insufficiency on the hepatic clearance of some drugs. International Journal of Clinical Pharmacology Research 6: 459–474, 1983
Bergan T. Pharmacokinetics of oral quinolones. Proceedings of the 6th Mediterranean Congress of Chemotherapy. Taormina. May 22–27, 1988. Abstract no. 60. p.22, 1988
Bergan T, Thorsteinsson SB, Kolstad IM, Johnsen S. Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. European Journal of Clinical Microbiology 5: 187–192, 1986
Bremner DA, Dickie AS, Singh KP. In vitro activity of fleroxacin compared with three other quinolones. Journal of Antimicrobial Chemotherapy 22 (Suppl. D): 19–25, 1988
Chin N, Brittain DC, Neu HC. In vitro activity of Ro 23-6240. a new fluorinatcd 4-quinolone. Antimicrobial Agents and Chemotherapy 29: 675–680, 1986
De Lepeilere I, van Hecken A, Verbesselt R, Tjandra Maga TB, De Schepper PJ. Comparative oral pharmacokinetics of fleroxacin and pefloxacin. Journal of Antimicrobial Chemotherapy 22: 197–202, 1988
Dell D, Partos C, Portmann R. The determination of a new trifluorinated quinolonc, fleroxacin, its N-demethyl and N-oxide metabolites in plasma and urine by high performance liquid chromatography with fluorescence detection. Journal of Liquid Chromatography 11: 1299–1312, 1988
Fillastre JP. Quinolones and renal failure. Quinolones Bulletin 4: 1–8, 1988
Gotch FA. Haemodialysis: technical and kinetic considerations. In Brenner & Rector (Eds) The kidney, pp. 1672–1704, WB Saunders Company. Philadelphia. 1976
Griggs DJ, Wise R, Kirkpatrick B, Ashby JP. The metabolism and pharmacokinetics of fleroxacin in healthy subjects. Journal of Antimicrobial Chemotherapy 22(Suppl. D): 191–194, 1988
Hirai K, Aoyama K, Hosaka M, Oomari Y, Niwata Y, et al. In vitro and in vivo antibacterial activity of AM 833, a new quinolonc derivative. Antimicrobial Agents and Chemotherapy 29: 1059–1066, 1986
Hoffler D, Pech M, Koeppe P, Metz R, Sorgel F. Pharmacokinetics and dose recommendations of fleroxacin in subjects with normal and impaired renal function. Acta Therapeutica 14: 121–134, 1988
Houston JB. Drug metabolite kinetics. Pharmacology and Therapeutics 15: 521–552, 1982
Jungers P, Ganeval D, Hannedouche T, Prieur B, Montay G. Steady state levels of pefloxacin and its metabolites in patients with severe renal impairment. European Journal of Clinical Pharmacology 33: 463–467, 1987
Lee CC, Marbury TC. Drug therapy in patients undergoing hemodialysis: clinical pharmacokinetic considerations. Clinical Pharmacokinetics 9: 42–66, 1984
Manek N, Andrews JM, Wise R. In vitro activity of Ro 23-6240, a new trifluoro-quinolone derivative, compared with that of other antimicrobial agents. Antimicrobial Agents and Chemotherapy 30: 320–332, 1986
Montay G, Jacquot C, Bariety J, Cunci R. Pharmacokinetics of pefloxacin in renal insufficiency. European Journal of Clinical Pharmacology 29: 345–349, 1985
Panneton AC, Bergeron MG, Le Bel M. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400 and 800mg dosage regimens. Antimicrobial Agents and Chemotherapy 32: 1515–1520, 1988
Pohlod DJ, Saravolatz LD, Somerville MM. In vitro susceptibility of staphylococci to fleroxacin in comparison with six other quinolones. Journal of Antimicrobial Chemotherapy 22 (Suppl. D): 35–43, 1988
Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP. Pharmacokinctics of ciprofloxacin tablets in renal failure: influence of haemodialysis. European Journal of Clinical Pharmacology 31: 589–593, 1987
Sorgel F, Metz R, Naber K, Seelmann R, Muth P. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 22 (Suppl. D): 155–167, 1988a
Sorgel F, Scelmann R, Naber K, Metz R, Muth P. Metabolism of fleroxacin in man. Journal of Antimicrobial Chemotherapy 22 (Suppl. D): 169–178, 1988b
Sullan E, Richard C, Pezzano M, Auzepy Ph, Singlas E. Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. European Journal of Clinical Pharmacology 34: 637–643, 1988
Teunisscn MW, Kampf D, Roots I, Vermeulen NPE, Breimer DD. Antipyrine metabolite formation and excretion in patients with chronic renal failure. European Journal of Clinical Pharmacology 28: 584–595, 1985
Weidekamm E, Hermann P, Stuck A, Frey F. Single dose pharmacokinetics of fleroxacin in healthy volunteers and renal diseased patients. Proceedings of the 27th ICAAC. New York. October 4–7, 1987. Abstract no. 1264. p. 317, 1987b
Weidekamm E, Portmann R, Suter K, Partos C, Dell D, et al. Single and multiple dose pharmacokinetics of fleroxacin, a trifluonnated quinolone, in humans. Antimicrobial Agents and Chemotherapy 31: 1909–1914, 1987a
Wise R, Kirkpatrick B, Ashby J, Griggs DJ. Pharmacokinetics and tissue penetration of RO 23-6240, a new trifluoroquinolone. Antimicrobial Agents and Chemotherapy 31: 161–163, 1987
Wise R, Lister D, McNulty CAM, Griggs D, Andrews JM. The comparative pharmacokinetics of five quinolones. Journal of Antimicrobial Chemotherapy 18 (Suppl. D): 71–81, 1986
Yamaoka K, Nakagawa T, Uno T. Statistical moment in pharmacokinetics. Journal of Pharmacokinelics and Biopharmaceutics 6: 547–558, 1978
Zeiler HJ, Petersen U, Gau W, Ploschke HJ. Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay. Arzneimittel-Forschung 37: 131–134, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Singlas, E., Leroy, A., Sultan, E. et al. Disposition of Fleroxacin, a New Trifluoroquinolone, and Its Metabolites. Clin Pharmacokinet 19, 67–79 (1990). https://doi.org/10.2165/00003088-199019010-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199019010-00005